D A Erlanson1, A C Braisted, D R Raphael
1Sunesis Pharmaceuticals, Incorporated, Redwood City, CA 94063, USA. erlanson@sunesis-pharma.com
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
A new "tethering" strategy enables discovery of weak-binding ligands for proteins. This method rapidly identifies and optimizes drug leads, as demonstrated by developing a potent thymidylate synthase inhibitor.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: